IP Library › Granted Patent US 12,208,078
Granted Patent B2
US 12,208,078 · App. 18/055,778 · Granted Jan 28, 2025

Tiglien-3-one derivatives

Inventors: Paul Warren Reddell (Yungaburra, AU); Victoria Anne Gordon (Yungaburra, AU)
Assignee: QBIOTICS PTY LTD
A61K31/336A01N43/20A01N43/90A01N45/00A01N53/00A61K9/0014A61K9/0019A61K9/06A61K47/10C07D301/32C07D303/14C07D303/17C07D303/32C07D303/44C07D493/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,208,078
App. No.
18/055,778
Granted
Jan 28, 2025
Kind
B2
Abstract

The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.

Claims (36)

1. A method of treating a protein kinase C activator-responsive cell proliferative disorder, comprising:

administering to a subject in need thereof an effective amount of 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:

wherein the cell proliferative disorder is a solid tumor or a dermatological neoplasm.

2. The method of 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the subject is an animal.

4. The method of claim 3 , wherein the animal is a horse.

5. The method of claim 3 , wherein the subject is a dog.

6. The method of claim 1 , wherein administration is by injection.

7. The method of claim 1 , further comprising administration of an anti-inflammatory agent.

8. A method of treating a protein kinase C activator-responsive cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:

and a pharmaceutically acceptable carrier, diluent and/or excipient,

wherein the cell proliferative disorder is a solid tumor or a dermatological neoplasm.

9. The method of claim 8 , wherein the subject is a human.

10. The method of claim 8 , wherein the subject is an animal.

11. The method of claim 10 , wherein the animal is a horse.

12. The method of claim 10 , wherein the animal is a dog.

13. The method of claim 8 , wherein administration is by injection.

14. The method of claim 8 , further comprising administration of an anti-inflammatory agent.

15. A method of treating a protein kinase C activator-responsive cell proliferative disorder, comprising:

administering to a subject in need thereof an effective amount of 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:

wherein the cell proliferative disorder is selected from the group consisting of melanoma, squamous cell carcinoma, sarcoma, fibrosarcoma, lymphoma, breast cancer, colon cancer, basal cell carcinoma, sarcoids, and equine sarcoids.

16. The method of claim 15 , wherein the subject is a human.

17. The method of claim 15 , wherein the subject is an animal.

18. The method of claim 17 , wherein the animal is a horse.

19. The method of claim 17 , wherein the subject is a dog.

20. The method of claim 15 , wherein administration is by injection.

21. The method of claim 15 , further comprising administration of an anti-inflammatory agent.

22. A method of treating a protein kinase C activator-responsive cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:

and a pharmaceutically acceptable carrier, diluent and/or excipient,

wherein the cell proliferative disorder is selected from the group consisting of melanoma, squamous cell carcinoma, sarcoma, fibrosarcoma, lymphoma, breast cancer, colon cancer, basal cell carcinoma, sarcoids, and equine sarcoids.

23. The method of claim 22 , wherein the subject is a human.

24. The method of claim 22 , wherein the subject is an animal.

25. The method of claim 24 , wherein the animal is a horse.

26. The method of claim 24 , wherein the subject is a dog.

27. The method of claim 22 , wherein administration is by injection.

28. The method of claim 22 , further comprising administration of an anti-inflammatory agent.

Priority Claims (1)
AU 2005907278 · Dec 23, 2005 · national
Continuity (8)
Division 17204747 · Mar 17, 2021
Continuation 16702296 · Dec 3, 2019
Continuation 16149977 · Oct 2, 2018
Continuation 15426744 · Feb 7, 2017
Continuation 15041960 · Feb 11, 2016
Division 14084949 · Nov 20, 2013
Division 12158461
Related Publication 20230301960A1 · Sep 28, 2023
References Cited (44)
US 6268395B1 · Hattori · 2001 [cited by applicant]
US 8598229B2 · Reddell et al. · 2013 [cited by applicant]
US 9289410B2 · Reddell · 2016 [cited by examiner]
US 9770431B2 · Reddell · 2017 [cited by examiner]
US 10543188B2 · Reddell · 2020 [cited by examiner]
US 10980769B2 · Reddell · 2021 [cited by examiner]
US 11213506B2 · Reddell · 2022 [cited by examiner]
US 20220193023A1 · Gordon · 2022 [cited by examiner]
US 20220313648A1 · Thomas · 2022 [cited by examiner]
Polsky, D.; Cordon-Cardo, C. “Oncogenes in melanoma” 2003, Oncogene, vol. 22, pp. 2087-3091. (Year: 2003). [cited by examiner]
Swannie, H. C.; Kaye, S. B. “Protein Kinase C Inhibitors” 2002, Current Oncology Reports, vol. 4, pp. 37-46. (Year: 2002). [cited by examiner]
Boyle, G. M.; et al. “Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models” 2014, PLOS One, vol. 9, e108887. (Year: 2014). [cited by examiner]
Panizza, B. J.; et al. “Phase I dose escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)” 2019, EBioMedicine, vol.… [cited by examiner]
Finkelstein, S.; Grubb, P. J. “ Lipid concentration in the embryo-endosperm fraction of seeds of Australian tropical lowland rainforest trees: relevance to defence and dispersal” 2002, Seed Science Research, vol. 12, pp… [cited by examiner]
Goldberg, E. P.; et al. “Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery” 2002, Journal of Pharmacy and Pharmacology, vol. 54, pp. 159-180. (Year: 2002). [cited by examiner]
Theon, A. P.; et al. “Intratumoral chemotherapy with cisplatin in oily emulsion in horses” 1993, J. Am. Vet. Med. Assoc., vol. 202, pp. 261-267. (Year: 1993). [cited by examiner]
Wennerberg, J.; et al. “The Effect of Cisplatin and Fluorouracil on Xenografted Human Squamous Cell Carcinoma of the Head and Neck” 1988, Arch Otolaryngol Head Neck Surgery, vol. 149, pp. 571-578. (Year: 1988). [cited by examiner]
Knapp, D. W.; et al. “Cisplatin Therapy in 41 Dogs With Malignant Tumors” 1988, Journal of Veterinary Internal Medicine, vol. 2, pp. 41-46. (Year: 1988). [cited by examiner]
Steinberg, D.; Friedman, M. “Development of Sustained-Release Devices for Modulation of Dental Plaque Biofilm and Treatment of Oral Infectious Diseases” 2000, Drug Development Research, vol. 50, pp. 555-565. (Year: 2000… [cited by examiner]
Gilson, R. J. C.; et al. “A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients” 1999, Aids, vol. 13, pp. 2397-2404. (Year: 1999). [cited by examiner]
Ward, R. S.; Saffle, J. R. “Topical Agents in Burn and Wound Care” 1995, Physical Therapy, vol. 75, pp. 526-538. (Year: 1995). [cited by examiner]
Kortmansky, J.; et al. “Bryostatin-1: A Novel PKC Inhibitor in Clinical Development” 2003, Cancer Investigation, vol. 21, pp. 924-936. (Year: 2003). [cited by examiner]
Brynes et al., “Plasminogen Activator Induction and Platelet Aggregation by Phorbol and Some of Its Derivatives: Correlation with Skin Irritancy and Tumor-promoting Activity,” [cited by applicant]
CA Abstract No. 101:147806, taken from Adolf et al., “On the active principles of the spurge family, X. Skin irritants, cocarcinogens, and cryptic cocarcinogens from the latex of the manchineel tree,” [cited by applicant]
CA Abstract No. 115:273076, taken from Roeser et al., “Toxicokinetics of tumor promoters of mouse skin. II. Metabolism of the tumor promoter 12-O-tetradecanoylphorbol 13-acetate in mouse skin and biological activities o… [cited by applicant]
CA Abstract No. 69:10570, taken from Crombie et al., “Chemistry and structure of phorbol, the diterpene parent of the cocarcinogens of croton oil,” [cited by applicant]
CA Abstract No. 70:47622, taken from Schairer et al., “Chemistry of phorbol. IV. Polybenzoates and polyacertates of phorbol and 3-phorbolol and functional derivatives of the allyl group of phorbol,” [cited by applicant]
CA Abstract No. 88:37991, taken from Snatzke et al., “Chemistry of phorbol. XIX. On circular dichroism. LXX. Chiroptical properties of phorbol-12,13,20-triacetate and some other phorbol derivatives,” [cited by applicant]
CA Abstract No. 89:192165, taken from Brune et al., “Inflammatory, tumor initiating and promoting activities of polycyclic aromatic hydrocarbons and diterpene esters in mouse skin as compared with their prostaglandin re… [cited by applicant]
CA Abstract No. 89:3208, taken from Ogura et al., “Potential anticancer agents. VIII. Constituents of Baliospermum montanum (Euphorbiaceae),” [cited by applicant]
CA Abstract No. 92:141462, taken from Freeman et al., “The constituents of Australian Pimelea species I. The isolation and structure of the toxin of Pimelea simplex and P. trichostachya Form B responsible for St. George… [cited by applicant]
CA Abstract No. 93:232311, taken from Goerttler et al., “Two-stage carcinogenesis in NMRI mice: intravaginal application of 7,12-dimethylbenz [a] anthracene as initiator followed by the phorbol ester 12-O-tetradecanoylp… [cited by applicant]
CA Abstract No. 97:176609, taken from Zayed et al., “On the active principles of the Thymelaeaceae. I. The irritants and cocarcinogens of Pimelea prostrata,” [cited by applicant]
Challacombe et al., “Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate,” [cited by applicant]
Cozzi et al., “Induction of Senescence in Diterpene Ester-Treated Melanoma Cells via Protein Kinase C-Dependent Hyperactivation of the Mitogen-Activated Protein Kinase Pathway,” [cited by applicant]
Hafez et al., “Active Principles of the Thymelaeaceae,” [cited by applicant]
Hampson et al., “PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC,” [cited by applicant]
Mackenzie et al., “Addressing the current challenges to finding new anthelminthic drugs,” [cited by applicant]
Page et al., “Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?” [cited by applicant]
Silver, “Challenges of Antibacterial Discovery,” [cited by applicant]
Tyler et al., “Synthesis and Structure-Activity Studies of Potential Antitumour Agents Derived from Esters of Phorbol,” [cited by applicant]
De Ridder et al., “Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46)”, [cited by applicant]
Miller et al., “Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors”, [cited by applicant]
Panizza et al., “Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)”, [cited by applicant]